Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_assertion type Assertion NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_head.
- NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_assertion description "[TOP2A aberrations (amplification, deletion) are found in up to approximately 30-90 % of HER2 amplified breast cancer and amplifications are more common than deletions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_provenance.
- NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_assertion evidence source_evidence_literature NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_provenance.
- NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_assertion SIO_000772 19365520 NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_provenance.
- NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_assertion wasDerivedFrom befree-2016 NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_provenance.
- NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_assertion wasGeneratedBy ECO_0000203 NP732256.RAYyP__613Hrsu_segO6KgIEv_lc0M0rR0lnFotZZwZJ0130_provenance.